By recovering exocrine pancreatic function (PABA) and dropping TGF-β1, TGFβRII, and the Smad3 protein level, SSHT was also verified as a chronic pancreatitis therapy in rats [97]. This evidence concerns the gene SMAD3 and chronic pancreatitis.